Grifols (GRFS) Invested Capital (2010 - 2025)
Grifols (GRFS) reported Invested Capital of $17.4 billion for Q4 2025, up 138.32% on a YoY basis from $7.3 billion in Q4 2024, and up 138.32% quarter-over-quarter from $7.3 billion in Q4 2024.
Grifols (GRFS) Invested Capital (2010 - 2025) Analysis & Trends
Grifols has reported Invested Capital for 16 years, with the latest figure at $17.4 billion in Q4 2025.
- For the quarter ending Q4 2025, Invested Capital rose 138.32% year-over-year to $17.4 billion; the trailing twelve-month figure through Dec 2025 stood at $17.4 billion (up 138.32% YoY), and the FY2025 full-year result was $17.4 billion, up 138.32% from the prior year.
- Invested Capital for Q4 2025 stood at $17.4 billion, up from $7.3 billion in the prior quarter.
- The five-year high for Invested Capital was $20.0 billion in Q4 2023, with the low at $7.3 billion in Q4 2024.
- Historically, Invested Capital has averaged $16.7 billion across 5 years, with a median of $19.1 billion in 2022.
- Annual changes were most pronounced in 2021 — Invested Capital jumped 149.24% — and 2024, when it plunged 63.54%.
- Grifols' Invested Capital stood at $19.5 billion in 2021, then declined by 2.1% to $19.1 billion in 2022, then climbed by 4.53% to $20.0 billion in 2023, then sank by 63.54% to $7.3 billion in 2024, then surged by 138.32% to $17.4 billion in 2025.
- The last three Invested Capital figures came in at $17.4 billion (Q4 2025), $7.3 billion (Q4 2024), and $20.0 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 72.79 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 98.65 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -6.66 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 48.32 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 66.51 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 45.69 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 90.96 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 64.21 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 17.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.36 Bn |
| Dec 31, 2024 | 7.28 Bn |
| Dec 31, 2023 | 19.98 Bn |
| Dec 31, 2022 | 19.11 Bn |
| Dec 31, 2021 | 19.52 Bn |
| Dec 31, 2020 | 7.83 Bn |
| Sep 30, 2020 | 373.69 Mn |
| Mar 31, 2020 | 365.85 Mn |
| Dec 31, 2019 | 15.56 Bn |
| Sep 30, 2019 | 462.26 Mn |
| Dec 31, 2018 | 12.64 Bn |
| Sep 30, 2018 | 287.95 Mn |
| Jun 30, 2018 | 4.98 Bn |
| Mar 31, 2018 | 405.38 Mn |
| Dec 31, 2017 | 11.41 Bn |
| Jun 30, 2017 | 4.10 Bn |
| Dec 31, 2016 | 9.36 Bn |
| Sep 30, 2016 | 4.19 Bn |
| Jun 30, 2016 | 4.09 Bn |
| Mar 31, 2016 | 15.11 Mn |